MARKET

PULM

PULM

Pulmatrix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.18
+0.15
+2.98%
Closed 16:00 05/27 EDT
OPEN
5.02
PREV CLOSE
5.03
HIGH
5.22
LOW
5.02
VOLUME
24.59K
TURNOVER
106.62K
52 WEEK HIGH
23.40
52 WEEK LOW
4.831
MARKET CAP
17.55M
P/E (TTM)
-0.6238
1D
5D
1M
3M
1Y
5Y
Pulmatrix GAAP EPS of -$1.51 misses by $0.10, revenue of $1.16M beats by $0.09M
Pulmatrix press release (NASDAQ:PULM): Q1 GAAP EPS of -$1.51 misses by $0.10. Revenue of $1.16M (-16.5% Y/Y) beats by $0.09M.
Seekingalpha · 05/12 13:17
Pulmatrix Q1 EPS $(1.51) Up From $(1.80) YoY, Sales $1.16M Down From $1.39M YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(1.51) per share. This is a 16.11 percent increase over losses of $(1.80) per share from the same period last year. The company reported $1.16 million in sales this
Benzinga · 05/12 13:07
-- Earnings Flash (PULM) PULMATRIX Posts Q1 Revenue $1.2M
MT Newswires · 05/12 09:22
BRIEF-Pulmatrix Inc Says On April 14, Appointed Peter Ludlum As Interim CFO Effective As Of April 18, 2022
reuters.com · 04/15 22:15
--HC Wainwright Adjusts Pulmatrix's Price Target to $10 from $5, Keeps Buy Rating
MT Newswires · 03/30 09:48
Pulmatrix GAAP EPS of -$8.63 misses by $0.83, revenue of $5.17M
Pulmatrix press release (NASDAQ:PULM): FY GAAP EPS of -$8.63 misses by $0.83. Revenue of $5.17M (-59.1% Y/Y).
Seekingalpha · 03/29 13:15
Pulmatrix FY21 EPS $(8.63) Up From $(13.43) YoY, Sales $5.17M Down From $12.63M YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(8.63) per share. This is a 35.74 percent increase over losses of $(13.43) per share from the same period last year. The company reported $5.17 million in sales this
Benzinga · 03/29 13:11
-- Earnings Flash (PULM) PULMATRIX Posts Q4 Revenue $5.2M
MT Newswires · 03/29 09:25
More
No Data
Learn about the latest financial forecast of PULM. Analyze the recent business situations of Pulmatrix through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PULM stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
High10.00
Average10.00
Low10.00
Current 5.18
EPS
Actual
Estimate
-2.75-2.50-2.25-2.00
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 23
Institutional Holdings: 557.94K
% Owned: 16.47%
Shares Outstanding: 3.39M
TypeInstitutionsShares
Increased
3
59.00K
New
4
1.41K
Decreased
5
28.76K
Sold Out
12
104.58K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Michael Higgins
President/Chief Executive Officer/Director
Teofilo Raad
Chief Financial Officer
Peter Ludlum
Vice President - Finance
Michelle Siegert
Director
Anand Varadan
Independent Director
Richard Batycky
Independent Director
Todd Bazemore
Independent Director
Christopher Cabell
No Data
No Data
About PULM
Pulmatrix, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing inhaled therapies to address serious respiratory disease. The Company designs and develops inhaled therapeutic products based on its dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The Company's therapeutic candidates includes Pulmazole, for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma and in patients with cystic fibrosis (CF), PUR1800, for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and PUR3100, for the treatment of acute migraine. The Company's each of this program is enabled by its iSPERSE formulation, designed to achieve specific therapeutic objectives.

Webull offers kinds of Pulmatrix Inc stock information, including NASDAQ:PULM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PULM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PULM stock methods without spending real money on the virtual paper trading platform.